Increased Incidence and Risk of Hair Loss with Glucagon-Like Peptide 1 Receptor Agonists: A Real-World Multicenter Cohort Study

This study investigated the association between glucagon-like peptide-1 receptor agonists (GLP-1RA) and hair loss, using data from over 1 million patients. The results showed that GLP-1RA therapy was linked to an increased incidence of telogen effluvium (TE), androgenic alopecia (AGA), and overall non-scarring hair loss (NSHL) in adults, but not alopecia areata (AA). At 12 months, the adjusted odds ratios for TE, AGA, and NSHL were significantly elevated. The study suggests that patients starting GLP-1RA should be informed about the potential risk of hair loss, and those experiencing new-onset shedding should undergo nutritional and endocrine evaluations, with early dermatology referrals recommended.